(51) International Patent Classification 6 :		(11) International Publication Number:	**WO 99/15532**
C07D 499/18, 501/12, C12P 37/04, 35/04	A1	(43) International Publication Date:	April 1999 (01.04.99)

(54) Title: PROCESS FOR RECOVERY OF A β-LACTAM ANTIBIOTIC

(57) Abstract

Process for recovery of a β-lactam antibiotic from a mixture containing β-lactam antibiotic and D-phenyl glycine (FG) in solution, with the mixture being brought to a pH between 3 and 8 at a temperature between –5 and 20 °C and at a concentration such that FG remains in solution, the solid β-lactam antibiotic obtained being recovered and the remaining liquid being subjected to a temperature increase to a temperature between 10 and 60 °C, with formation of solid FG, FG being separated out as a solid, and the mother liquor being at least partially recirculated. Use is preferably made of an initial mixture substantially containing β-lactam antibiotic and FG originating from an enzymatic acylation reaction in which the corresponding β-lactam nucleus, in particular 6-aminopenicillanic acid, 7-aminodesacetoxycephalosporanic acid and 7-amino-3-chloro-cet-3-em-4-carboxylic acid, is acylated with a D-phenyl glycine derivative.

Printed from Mimosa

PROCESS FOR RECOVERY OF A β-LACTAM ANTIBIOTIC

5

The invention relates to a process for recovery of a β-lactam antibiotic from a mixture substantially containing β-lactam antibiotic and D-phenyl glycine (FG) in solution, with the mixture being
10   brought to a pH between 3 and 8 at a temperature between -5 and 20°C and at a concentration such that FG remains in solution, the solid β-lactam antibiotic obtained being recovered and the remaining liquid being subjected to a temperature increase to a temperature
15   between 10 and 60°C, with formation of solid FG, FG being separated out as a solid, and the mother liquor being recirculated.

In general, in the preparation of β-lactam antibiotics involving the acylation of a β-lactam
20   nucleus with a derivative of D-phenyl glycine, the β-lactam antibiotic is difficult to recover and the reaction mixture is difficult to work up. Working up often involves substantial losses of valuable components, in particular the β-lactam antibiotic,
25   partly in the form of solubility losses and partly because of degradation as a result of the limited stability of β-lactam antibiotics.

The invention provides a new concept for recovery of β-lactam antibiotics whereby, in a simple
30   process that can be applied on an industrial scale, the losses of β-lactam antibiotics are strongly reduced and also valuable D-phenyl glycine is recovered. The

invention is based on the fact that it has been found
that FG can be heavily supersaturated, at relatively
low temperature, in the solution containing FG and the
antibiotic and can remain so for a long time without FG

5   precipitating or crystallizing out. In consequence, it
is possible to selectively recover the β-lactam
antibiotic at low temperature by isolating it, after
crystallizing, through a pH shift which does not cause
the FG to crystallize out. Furthermore, it has been

10   found that increasing the temperature of the mother
liquor causes FG to crystallize out rapidly whilst the
β-lactam antibiotic does not crystallize out. In this
manner, FG can be recovered selectively. In the
aforementioned manner, complete separation between β-

15   lactam antibiotic and FG can be effected.

        During the acylation reaction of the lactam
nucleus and a suitable acylation agent, in particular
an enzymatic acylation reaction with for example an
amide of D-phenyl glycine, for example D-phenyl glycine

20   amide (FGA) or an ester of D-phenyl glycine, for
example the methyl ester of D-phenyl glycine (FGM), the
acylation agent hydrolyzes with the β-lactam antibiotic
to form D-phenyl glycine (FG).

        The mixtures obtained after an acylation

25   reaction may contain, besides the β-lactam antibiotic
and FG, for example as yet unconverted β-lactam nucleus
and/or acylation agent, for example FGA or FGM. It has
been found that the exact compositions of the mixtures
that may be applied in the process according to the

30   invention are not particularly critical. Mixtures that
may suitably be applied in the process according to the
invention are preferably mixtures containing 10-1500
mM, in particular 50-1000 mM, β-lactam antibiotic; 0-
1500 mM, in particular 0-1000 mM FG, 0-1000 mM, in

particular 0-200 mM β-lactam nucleus and 0-1000, in particular 0-400 mM D-phenyl glycine derivative.

The mixture of β-lactam antibiotic and FG is brought to such concentration and pH that all components, in particular the components mentioned, are dissolved. To that end, the pH is preferably chosen to be low , for example between 0 and 3, in particular between 0.3 and 2. When the process is carried out on a large scale, a more or less continuous working-up process is preferably opted for. A continuous dissolving process allows a shorter residence time at relatively high or low pH. If desired, any solid components still present can be separated out by for example filtration or ultrafiltration.

According to the invention, the mixture, which may still contain solid β-lactam antibiotic, is first brought to a pH between 3 and 8, preferably between 5.5 and 8, in particular between 6.5 and 7, with measures being taken, for example adding water, to ensure that the concentration of the reactants, in particular FG, is such that the reactants, optionally with the exception of the β-lactam antibiotic, remain in solution whether or not supersaturated. The temperature is between -5 and 20°C, preferably between -3 and 15°C, in particular between 0 and 10°C. The temperature is kept relatively low, because it has surprisingly been found that FG can be heavily supersaturated under these condition, without FG precipitating.

Furthermore, it has been found that a temperature increase of the mother liquor remaining after separation of the β-lactam antibiotic causes FG to crystallize rapidly in the form of large crystals that can be filtered readily. The temperature is

increased to a value between 10 and 60°C, preferably to a value between 12 and 50°C, in particular between 15 and 40°C, in which process the pH of the mixture may in principle be varied in the range from 3 to 8. The pH

5   preferably is between 5.5 and 8, in particular between 6.5 and 7.5.

Now that the FG has crystallized out, the concentration has diminished so that, after being cooled, the mother liquor remaining after

10   crystallization and separation of FG can at least partially be recirculated to for example the dissolving vessel, which also receives a fresh mixture of β-lactam antibiotic and FG. Such recirculation preferably takes place at such a rate that FG remains in solution in the

15   dissolving vessel and remains supersaturated in the β-lactam antibiotic crystallization vessel. Since the FG mother liquor can at least partially be reused for β-lactam antibiotic crystallization, the solubility losses can be kept low. The degradation losses, too,

20   are relatively low because of the favourable process conditions.

The process is preferably carried out continuously, with a fresh mixture of β-lactam antibiotic and FG being added all the time and a small

25   proportion of for example the FG crystallization mother liquor being discharged all the time. Preferably, the flow of the discharge stream is chosen so that the volume of the process stream at various points in the process remains constant in time. In a continuous

30   process, the discharge stream can in principle be smaller. A possible process scheme is given in Figure 1 by way of illustration.

The process according to the invention can suitably be applied in the preparation of such β-lactam

antibiotics as have a phenyl glycine side chain, for
example cefalexin, ampicillin, cefaclor, pivampicillin,
becampicillin, talampicillin and cefaloglycine.

Any β-lactam nucleus can in principle be
used, in particular a β-lactam nucleus with the general
formula (1)

where R_0 represents H or an alkoxy group having 1-3 C
atoms; Y represents CH_2, O, S or an oxidized form of
sulphur; and Z represents

where R_1 represents for example H, OH, halogen, an
alkoxy group having 1-5 C atoms, an alkyl group having
1-5 C atoms, a cycloalkyl group having 4-8 C atoms, an
aryl or a heteroaryl group having 6-10 C atoms in which
the groups may or may not be substituted with for
example an alkyl, an aryl, a carboxy or an alkoxy group
having 1-8 C atoms; and where the carboxylic acid group
may be an ester group if so desired.

Suitable examples of β lactam nuclei that
may be employed in the process according to the
invention are penicillin derivatives, for example 6-
aminopenicillanic acid (6-APA) and cephalosporanic acid
derivatives, for example a 7-aminocephalosporanic acid
with or without a substituent at the 3-site, for
example 7-aminocephalosporanic acid (7-ACA), 7-

aminodesacetoxycephalosporanic acid (7-ADCA) and 7-
amino-3-chloro-cef-3-em-4-carboxylic acid (7-ACCA).

        In principle, any enzyme that is suitable
as a catalyst in the coupling reaction can be used as
5   the enzyme. Such enzymes include the enzymes
collectively referred to as penicillin amidase or
penicillin acylase. Such enzymes are described in for
example J.G. Shewale et al., Process Biochemistry,
August 1989, pp. 146-154 and in J.G. Shewale et all,
10 Process Biochemistry International, June 1990, pp. 97-
103. Examples of suitable enzymes are enzymes derived
from Acetobacter, , in particular Acetobacter
pasteurianum, Aeromonas, Alcaligenes, in particular
Alcaligenes faecalis, Aphanocladium, Bacillus sp., in
15 particular Bacillus megaterium, Cephalosporium,
Escherichia, in particular Escherichia coli,
Flavobacterium, Fusarium, in particular Fusarium
oxysporum and Fusarium Solani, Kluyvera, Mycoplana,
Protaminobacter, Proteus, in particular Proteus
20 rettgeri, Pseudomonas and Xanthomonas, in particular
Xanthomonas citrii.

        Preferably an immobilized enzyme is used,
since the enzyme can be easily isolated and re-used
then. A suitable immobilization technology is described
25 for instance in EP-A-222462. Another suitable
technology consists in immobilizing the Penicillin G
acylase on a carrier which contains a gelating agent,
for instance gelatin, and a polymer with free amino
groups, for instance alginate amine, chitosan or
30 polyethylene imine. In addition, enzymes may also be
utilized as a crystalline substance (CLEC's^{TM}).

        Particularly suitable enzymes among the
immobilized enzymes that are commercially available are
the Escherichia coli enzyme from Boehringer Mannheim
35 GmbH, which is commercially available under the name

Enzygel®, the immobilized Penicillin-G acylase from
Recordati and the immobilized Penicillin-G acylase from
Pharma Biotechnology Hannover.

In the (enzymatic) acylation reaction, the
5   acylation agent can be for instance a D-phenyl glycine
in activated form, preferably a (primary, secondary or
tertiary) amide or salt thereof, or a lower alkyl (1-
4C) ester, for instance a methyl ester.

The temperature at which the enzymatic
10 acylation reaction is effected usually is below 40°C,
preferably between -5 and 35°C. The pH at which the
enzymatic acylation reaction is effected usually is
between 5.5 and 9.5, preferably between 6.0 and 9.0.

The reaction preferably is stopped almost
15 completely when maximum conversion has been all but
achieved. A suitable embodiment for stopping the
reaction is to lower the pH, preferably to a value
between 4.0 and 6.3, in particular between 4.5 and 5.7.
Another suitable embodiment is to lower the temperature
20 of the reaction mixture on attaining the maximum
conversion. A combination of the two embodiments is
possible also.

Once the reaction has been stopped on
attaining the maximum conversion, the reaction mixture
25 usually is present in the form of a suspension
comprising a plurality of solids, for example the
antibiotic, D-phenyl glycine and, possibly, immobilized
enzyme. The immobilized enzyme preferably is recovered
in the interest of process economics. This can suitably
30 be accomplished for example by filtering the reaction
mixture on a sieve, while stirring, the stirrer's
direction of rotation being chosen so that the
suspension is pumped upwards at the centre of the
stirrer. Subsequently, valuable components such as the

antibiotic and FG can be recovered by the process according to the invention, with the solid components, possibly apart from solid antibiotic, being dissolved first, by means of for example a pH shift.

5   The pH may be lowered in several ways in the framework of the invention, for instance by adding an acid to the mixture. Suitable acids are for example mineral acids, in particular sulphuric acid, hydrochloric acid or nitric acid. Preferably,

10   hydrochloric acid is used. The pH can be raised by for example adding a base to the mixture. Suitable bases are for example inorganic bases, in particular ammonium hydroxide, potassium hydroxide or sodium hydroxide. Preferably, ammonium hydroxide is used.

15   In practice, the enzymatic acylation reaction and the working-up of the reaction mixture are usually effected in water. If desired, the reaction mixture may also contain an organic solvent or a mixture of organic solvents, preferably less than 30

20   vol.%. Examples of suitable organic solvents that can be used are alcohols having 1-7 C atoms, for example a monoalcohol, in particular methanol or ethanol; a diol, in particular ethylene glycol, or a triol, in particular glycerol.

25   The process according to the invention is particularly suited for being used in working up the reaction mixture obtained after the enzymatic acylation reaction in which 6-APA is acylated with an amide of D-phenyl glycine, for example FGA, or an ester of D-

30   phenyl glycine, for example FGM.

          In a preferred embodiment of the process measures are taken to ensure that the concentration of dissolved 6-APA in the reaction mixture is kept relatively low so that a higher conversion can be

35   achieved than when the concentration of dissolved 6-APA

is chosen to be as high as possible.

Moreover, it has been found that the stirrability of the reaction mixture is significantly higher when the concentration of dissolved 6-APA is
5 kept low.

In the present context, 'conversion' refers to the molar ratio of the ampicillin formed and the amount of 6-APA used. The concentration of dissolved 6-APA is expressed as the amount of 6-APA in moles per kg
10 of the reaction mixture; the total concentration, dissolved and undissolved, of 6-APA is expressed as the amount of 6-APA plus ampicillin in moles per kg of the total reaction mixture; the total reaction mixture may contain, besides the solution, a number of solids, for
15 example 6-APA, ampicillin, phenyl glycine and immobilized enzyme.

The molar ratio of acylation agent and 6-APA, i.e. the total amount of phenyl glycine derivative added, divided by the total amount of 6-APA added,
20 expressed in moles, is preferably less than 2.5. It is preferred for the molar ratio to be between 1.0 and 2.0, in particular between 1.2 and 1.8.

The enzymatic acylation reaction is preferably carried out as a batch process. If desired,
25 the reaction can also be carried out continuously, with in-line control of the concentration of dissolved 6-APA.

The total concentration of 6-APA plus ampicillin (in dissolved and undissolved form) in the
30 reaction mixture preferably is higher than 250 mM, more preferably higher than 300 mM, in particular higher than 350 mM.

In this preferred embodiment, the concentration of dissolved 6-APA during the preparation
35 of ampicillin is essentially kept below 300 mM.

preferably below 250 mM. At a higher concentration of
the acylation agent, the concentration of dissolved 6-
APA may optionally chosen to be higher than at a lower
concentration. This is because the rate of reaction is
5   higher at higher concentrations of the acylation agent,
so that 6-APA is dissolved in a high concentration for
only a relatively short period.

            The concentration of 6-APA dissolved in the
reaction mixture can be kept low in various ways. One
10   possibility of keeping the concentration of dissolved
6-APA low is to initially feed only a portion of the
total amount of 6-APA and to meter in the balance
during the reaction. A drawback of this is that in that
case 6-APA needs to be metered in solid form, which
15   presents practical problems. Therefore, it is preferred
in a batch process for the total amount of 6-APA to be
supplied at the start of the reaction, whereupon,
during the enzymatic acylation reaction, the
concentration of 6-APA in the reaction mixture will
20   decrease and the concentration of ampicillin will
increase. A suitable method of achieving a low
concentration of dissolved 6-APA is for example to keep
the pH at a lower value than that at which maximum
solubility of the reactants is achieved. A particularly
25   suitable method of keeping the dissolved 6-APA
concentration low is for example to ensure that the
concentration of the phenyl glycine derivative is kept
low, for example by metering in the phenyl glycine
derivative partly in the course of the reaction.

30   In this context, it has been found that, if
the concentration of the phenyl glycine derivative is
kept low, only little 6-APA is dissolved so that the
dissolved 6-APA concentration can be controlled by
metering the phenyl glycine derivative.

35   A particularly suitable embodiment is

obtained when FGA is added in the form of one of its
salts, preferably the salt of FGA and a mineral acid,
for example FGA.HCl, FGA.1/2H$_2$SO$_4$ and FGA.HNO$_3$. In this
manner it is possible to readily ensure optimum

5   metering of the FGA by keeping the pH constant.
Preferably, FGA.1/2H$_2$SO$_4$ is used inasmuch as this salt
possesses extremely high solubility.

           In the framework of the present
invention the various components may be present in the

10   reaction mixture in the free form or as salts. The pH
values mentioned are in all cases the pH values
measured at room temperature.

           The invention will be further elucidated by
means of the following examples, without however being

15   restricted thereto.

Abbreviations:

AMPI = ampicillin

20   AMPI.3H$_2$O = ampicillin trihydrate

6-APA = 6-amino-penicillanic acid

FGA = D-phenyl glycine amide

FG = D-phenyl glycine

FGHM = D-p-hydroxyphenyl glycine methyl ester

25   Assemblase™ is an immobilized Escherichia
coli penicillin acylase from E. coli ATCC 1105 as
described in WO-A-97/04086. The immobilization is
effected as set out in EP-A-222462, with gelatin and
chitosan being used as gelating agents and

30   glutaraldehyde as crosslinking agent.

           The ultimate activity of the Escherichia
coli penicillin acylase is determined by the amount of
enzyme added to the activated spherules and amounted to
3 ASU/g of dry weight, 1 ASU (Amoxicillin Synthesis

35   Unit) being defined as the amount of enzyme capable of

producing 1 g of Amoxicillin.3H₂O from 6-APA and FGHM
per hour (at 20°C; 6.5% 6-APA and 6.5% FGHM).

Example I

5   Preparation of FGA.1/H₂SO₄ solution

301.6 g of FGA (2.00 mole) were suspended
in 650 g of water at T = 5°C. 102.1 g of 96-% H₂SO₄
(1.00 mole) were added drop-wise in 1 hour while
stirring, with the temperature being kept at T < 25°C by
10 means of cooling.

Example II

Enzymatic synthesis of ampicillin

An enzyme reactor (1.5 l, diameter 11 cm),
15 fitted with a 175 µm mesh sieve bottom, was filled with
300 g of net-wet assemblase™ (the term net-wet refers
to the mass of the enzyme obtained on separating the
enzyme from an enzyme slurry with the aid of a glass
filter).

20 A preparation reactor (1.2 l) was filled
with 131.6 g of 6-APA (0.600 mole), 30.2 g of FGA
((0.200 mole) and 400 ml of water (T = 10°C). This
mixture was stirred for 15 minutes at T = 10°C and then
at t = 0 transferred into the enzyme reactor with the
25 aid of 100 ml of water (T = 10°C).

The stirrer in the enzyme reactor was
switched on at
t = 0. The temperature was kept at 10°C all the time.
423.7 g of FGA.½H₂SO₄ solution (0.800 mole) were added
30 at a constant rate over a period of 233 minutes. The pH
was approx. 6.3. From t = 295 minutes onwards the pH
was maintained at 6.3 by titrating with 6N H₂SO₄. At t =
570 minutes the amount of AMPI was maximum and the pH
was reduced to 4.7 by adding 6N H₂SO₄. The enzyme

reactor now contained:

575 mmole AMPI

15 mmole 6-APA

50 mmole FGA

5   365 mmole FG

Example III

Separation of AMPI/FG slurry from enzyme reactor

The AMPI/FG slurry prepared as described in
10   Example II was removed from the enzyme reactor via the
sieve bottom by means of stirred filtration. This was
done using a pitched-blade stirrer, which was
positioned at 0.5 cm over the sieve. Stirring was in
upward direction at approx. 500 rpm. The AMPI/FG slurry
15   separated from the reactor was filtered on a G3 glass
filter. The AMPI/FG wet cake was put aside and the
mother liquor was returned to the enzyme reactor,
whereupon stirred filtration followed by G3 filtration
of the AMPI/FG slurry resumed. The enzyme reactor was
20   washed with the AMPI/FG mother liquor in this fashion
until no more solid matter was flushed out of the
reactor. The last mother liquor collected in G3
filtration was combined with the AMPI/FG wet cake to
form an AMPI/FG slurry.
25   The AMPI/FG slurry so obtained contained >
99.0% of the total amount of AMPI produced in the
enzyme reactor and > 95.5% of the total amount of FG
produced in the enzyme reactor. After this stirred
filtration, > 99.5% of the Assemblase™ was present in
30   the enzyme reactor.

Example IV

Recrystallization of ampicillin

Recrystallization was effected in a rig
35   (Fig. 1) consisting of a storage vessel (V$_1$; 2 l), a

pump, a dissolving vessel (V₂; 0.05 l), a filter (F₂)
fitted with a Seitz filter plate, a pump, an AMPI
crystallization vessel (V₃; 0.5 l), two glass filters 1A
and 1B (F₁A and F₁B) arranged in parallel, a pump, a heat
exchanger, an FG crystallization vessel (V₄; 0.5 l), two
glass filters 2A and 2B (F₂A and F₂B) arranged in
parallel, a pump and lastly a heat exchanger connected
to the dissolving vessel. The line between filters 2A
and 2B and the dissolving vessel contained a three-way
valve enabling a portion of the stream to be
discharged. All vessels were provided with a stirrer, a
thermometer and a pH electrode.

The AMPI/FG slurry which was isolated as
described in Example III was quantitatively transferred
to the storage vessel and cooled to 2°C while being
stirred.

The recrystallization loop (from the
storage vessel up to the heat exchanger inclusive) was
filled with a total of approx. 1350 grams of initial
solution consisting of an aqueous solution of 0.6% AMPI
and 0.6% FG. The recrystallization loop (except the FG
crystallization vessel and the glass filters 2A and 2B)
was cooled to 1-2°C. The FG crystallization vessel and
the glass filters 2A and 2B were kept at 20°C.
Circulation in the recrystallization loop (flow = 1.2
litre per hour) was started. The pH in the dissolving
vessel was adjusted to pH = 1.25 by titration with 8N
HCl solution. The pH in the AMPI crystallization vessel
was adjusted to pH = 6.5 by titration with 25 wt.% NH₃
solution. 13.0 grams of AMPI.3H₂O were added to the AMPI
crystallization vessel as nuclei. 10.0 grams of FG
nuclei were added to the FG crystallization vessel.

Recrystallization was started at t = 0 by

metering the AMPI/FG slurry from the storage vessel to
the dissolving vessel (flow = 0.14 litre per hour). The
contents of the storage vessel were added to the
dissolving vessel in approx. 8 hours. The levels in the
5   dissolving vessel and the AMPI and FG crystallization
vessels remained constant throughout. This was
accomplished by discharging a proportion of the FG
mother liquor to the dissolving vessel rather than
recirculating it.

10   The AMPI slurry from the AMPI
crystallization vessel was filtered on glass filter 1A
without interruption while the mother liquor was being
pumped to the FG crystallization vessel. The FG slurry
from the FG crystallization vessel was filtered on
15   glass filter 2A and the mother liquor was pumped back
to the storage vessel. The AMPI/FG slurry from the
storage vessel and the FG mother liquor were mixed in
the dissolving vessel at a ratio of 1 to 8.6 throughout
the experiment. The storage vessel was empty after
20   approx. 8 hours and a total of 330 ml of 8N HCl
solution had been metered into the dissolving vessel.
           At t = 8 hours the storage vessel was
filled with fresh AMPI/FG slurry that had been isolated
as described in Example III. AMPI separation in the
25   recrystallization loop was switched from glass filter
1A to 1B and FG separation was similarly switched from
glass filter 2A to 2B.
           The AMPI wet cake on glass filter F1A was
washed with 2 x 175 ml of water (T = 5°C) and dried. The
30   FG wet cake on glass filter 2A was washed with 2 x 60
ml of water and dried.
           Recrystallization was carried out
continuously by filling the storage vessel with AMPI/FG
slurry every 8 hours and by alternately inserting and

emptying the glass filters 1A and 1B and 2A and 2B. The
flows of FG and mother liquor were approx. 0.18 litre
per hour on average.

The average yield per charge in the storage
vessel (600 mmoles of 6-APA metered into the enzyme
reactor in Example II) amounted to 220 grams of
AMPI.3H_2O (exclusive of AMPI nuclei; 91% relative to
600 mM of 6-APA) and 30 grams of FG (exclusive of FG
nuclei).

C L A I M S

1. Process for recovery of a β-lactam antibiotic from
    a mixture containing the β-lactam antibiotic and
    D-phenyl glycine (FG) in solution, with the
    mixture being brought to a pH between 3 and 8 at a
    temperature between -5 and 20°C and at a
    concentration such that FG remains in solution,
    the solid β-lactam antibiotic obtained being
    recovered and the remaining liquid being subjected
    to a temperature increase to a temperature between
    10 and 60°C, with formation of solid FG, FG being
    separated out as a solid, and the mother liquor
    being at least partially recirculated.

2. Process according to Claim 1, in which the
    temperature of the mixture is between -3 and 15°C.

3. Process according to Claim 2, in which the
    temperature of the mixture is between 0 and 10°C.

4. Process according to any one of Claims 1-3, in
    which the temperature in increased to a value
    between 12 and 50°C.

5. Process according to Claim 4, in which the
    temperature is increased to a value between 15 and
    40°C.

6. Process according to any one of Claims 1-5, in
    which the mixture is brought to a pH between 4 and
    7.

7. Process according to any one of Claims 1-6, in
    which the mother liquor is recirculated to the
    mixture containing dissolved β-lactam antibiotic
    and FG.

8. Process according to any one of Claims 1-7,

characterized in that the process is carried out continuously.

9.   Process according to any one of Claims 1-8, in which the initial mixture substantially containing β-lactam antibiotic and FG originates from an enzymatic acylation reaction in which the corresponding β-lactam nucleus is acylated with a D-phenyl glycine derivative.

10.   Process according to Claim 9 in which the mixture obtained after the acylation reaction is first subjected to a pH reduction to a pH between 0 and 3.

11.   Process according to Claim 10 in which the mixture is subjected to a pH reduction to a pH between 0.3 and 2.

12.   Process according to any one of Claims 1-11 in which the mixture contains 10-1500 mM β-lactam antibiotic, 0-1500 mM FG, 0-1000 mM D-phenyl glycine derivative and 0-1000 mM β-lactam nucleus.

13.   Process according to any one of Claims 1-12 in which the β-lactam nucleus is 6-aminopenicillanic acid (6-APA) and the β-lactam antibiotic is ampicillin.

14.   Process according to any one of Claims 1-12 in which the lactam nucleus is 7-aminodesacetoxycephalosporanic acid (7-ADCA) and the β-lactam antibiotic is cephalexin.

15   Process according to any one of Claims 1-12 in which the lactam nucleus is 7-amino-3-chloro-cef-3-em-4-carboxylic acid (7-ACCA) and the β-lactam antibiotic is cefaclor.

Fig 1.

INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6   C07D499/18   C07D501/10   C12P37/04   C12P35/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6   C07D   C12P   A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 97 22610 A (CHEMFERM V O.F.) 26 June 1997 see page 3, line 7 - page 4, line 19; claims ---	1-15
A	WO 96 30376 A (CHEMFERM V O.F.) 3 October 1996 see the whole document ---	1-15
A	WO 96 23796 A (CHEMFERM V O.F.) 8 August 1996 see the whole document ---	1-15
A	WO 95 03420 A (DSM N.V.) 2 February 1995 see the whole document ---	1-15

−/−−

[X] Further documents are listed in the continuation of box C   [X] Patent family members are listed in annex

Date of the actual completion of the international search	Date of mailing of the international search report
24 November 1998	01/12/1998

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl Fax: (+31-70) 340-3016	Chouly, J

Form PCT/ISA/210 (second sheet) (July 1992)

2

INTERNATIONAL SEARCH REPORT

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 034 522 A (F G. SCHREIBER) 23 July 1991 see claims	1-15

P,A	NL 1 002 818 C (CHEMFERM V.O.F.) 15 October 1997 see claims	1-15

Patent document cited in search report		Publication date	Patent family members		Publication date
WO 9722610	A	26-06-1997	AU	7711496 A	14-07-1997
			EP	0865443 A	23-09-1998
WO 9630376	A	03-10-1996	BE	1009264 A	07-01-1997
			AU	4958296 A	16-10-1996
			CN	1185157 A	17-06-1998
			CZ	9703074 A	14-01-1998
			EP	0869960 A	14-10-1998
WO 9623796	A	08-08-1996	BE	1009071 A	05-11-1996
			BE	1009194 A	03-12-1996
			BE	1009263 A	07-01-1997
			AU	4846196 A	21-08-1996
			AU	4846296 A	21-08-1996
			CZ	9702419 A	14-01-1998
			EP	0869961 A	14-10-1998
			EP	0815256 A	07-01-1998
			WO	9623897 A	08-08-1996
			PL	321626 A	08-12-1997
WO 9503420	A	02-02-1900	BE	1007296 A	09-05-1995
			AT	160589 T	15-12-1997
			CN	1127531 A	24-07-1996
			DE	69407049 D	08-01-1998
			DE	69407049 T	09-07-1998
			EP	0712443 A	22-05-1996
			ES	2110255 T	01-02-1998
US 5034522	A	23-07-1991	NONE		
NL 1002818	C	15-10-1997	NONE		